"Under the final rule, in human prescription drug ads that are presented direct-to-consumer (i.e., in television or radio format) that state the name of the drug and conditions of use, the statement relating to major side effects and contraindications (the “major statement”) must be presented in a clear, conspicuous, and neutral manner.
The effective date of the final rule is May 20, 2024, and the compliance date is November 20, 2024."
#FDA #Pharmaceuticals #BigPharma #DrugAds #Advertising #DirectToConsumer
https://www.policymed.com/2024/01/fda-releases-final-rule-for-direct-to-consumer-prescription-drug-advertisements.html?utm_source=feedblitz&utm_medium=FeedBlitzRss&utm_campaign=policymed
The effective date of the final rule is May 20, 2024, and the compliance date is November 20, 2024."
#FDA #Pharmaceuticals #BigPharma #DrugAds #Advertising #DirectToConsumer
https://www.policymed.com/2024/01/fda-releases-final-rule-for-direct-to-consumer-prescription-drug-advertisements.html?utm_source=feedblitz&utm_medium=FeedBlitzRss&utm_campaign=policymed